Johan Bussink
Overview
Explore the profile of Johan Bussink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
206
Citations
8484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garrett Fernandes M, Bussink J, Wijsman R, Gouw Z, Weiss A, Sijtsema N, et al.
Radiother Oncol
. 2025 Feb;
206:110821.
PMID: 39993599
Background And Purpose: Inconsistencies in identifying dose-limiting cardiovascular substructures for treating stage III non-small cell lung cancer (NSCLC) have hindered the implementation of cardiac sparing treatment planning guidelines. This study...
2.
Beerkens A, Heskamp S, Reinema F, Adema G, Span P, Bussink J
Clin Cancer Res
. 2025 Feb;
PMID: 39898881
Hypoxia is a common feature of solid tumors and is associated with a poor response to anticancer therapies. Hypoxia also induces metabolic changes, such as a switch to glycolysis. This...
3.
Raaijmakers K, Adema G, Bussink J, Ansems M
J Exp Clin Cancer Res
. 2024 Dec;
43(1):323.
PMID: 39696386
Cancer-associated fibroblasts (CAFs) represent a group of genotypically non-malignant stromal cells in the tumor micro-environment (TME) of solid tumors that encompasses up to 80% of the tumor volume. Even though...
4.
Kaas J, Verbeek M, Li W, van der Heide S, Verhagen A, Monshouwer R, et al.
Radiother Oncol
. 2024 Oct;
202:110601.
PMID: 39481607
Introduction: Healthcare systems contribute significantly to CO emissions, accounting for 7 % of emissions in the Netherlands. Understanding the environmental footprint of medical treatments can help identify opportunities for reducing...
5.
Boreel D, Beerkens A, Heskamp S, Boswinkel M, Peters J, Adema G, et al.
Clin Transl Radiat Oncol
. 2024 Oct;
49:100875.
PMID: 39469146
Introduction: Tumor hypoxia is a feature of many solid malignancies and is known to cause radio resistance. In recent years it has become clear that hypoxic tumor regions also foster...
6.
Boreel D, Sandker G, Ansems M, van den Bijgaart R, Peters J, Span P, et al.
Mol Imaging Biol
. 2024 Jul;
26(5):835-846.
PMID: 39009951
Introduction: Combined radiotherapy and immune checkpoint inhibition is a potential treatment option for head and neck squamous cell carcinoma (HNSCC). Immunocompetent mouse models can help to successfully develop radio- immunotherapy...
7.
Kleinendorst S, Oosterwijk E, Molkenboer-Kuenen J, Frielink C, Franssen G, Boreel D, et al.
Theranostics
. 2024 Jul;
14(9):3693-3707.
PMID: 38948062
Immune checkpoint inhibitors (ICI) are routinely used in advanced clear cell renal cell carcinoma (ccRCC). However, a substantial group of patients does not respond to ICI therapy. Radiation is a...
8.
Beerkens A, Boreel D, Nathan J, Neuzil J, Cheng G, Kalyanaraman B, et al.
Cancer Metab
. 2024 May;
12(1):13.
PMID: 38702787
Background: Hypoxia is a common feature of many solid tumors and causes radiotherapy and immunotherapy resistance. Pharmacological inhibition of oxidative phosphorylation (OXPHOS) has emerged as a therapeutic strategy to reduce...
9.
Garrett Fernandes M, Bussink J, Wijsman R, Stam B, Monshouwer R
Phys Imaging Radiat Oncol
. 2024 Jan;
29:100533.
PMID: 38292649
Background And Purpose: Normal tissue complication probability (NTCP) models are developed from large retrospective datasets where automatic contouring is often used to contour the organs at risk. This study proposes...
10.
Kaanders J, Bussink J, Aarntzen E, Braam P, Rutten H, van der Maazen R, et al.
Semin Radiat Oncol
. 2023 Jun;
33(3):287-297.
PMID: 37331783
PET imaging with 2'-deoxy-2'-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator...